Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Kyverna Therapeutics, Inc. - Common Stock (NQ:KYTX)

5.210 -0.460 (-8.11%)
Delayed Quote Updated: 3:07 PM EST, Nov 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Kyverna Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Kyverna Therapeutics Highlights Promising Updated Clinical Data with Miv-cel in Progressive Multiple Sclerosis at MS Toronto 2026
From Kyverna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Kyverna Therapeutics Presents Full One-Year Registrational Data Set Demonstrating Sustained Clinical Benefit of Miv-cel in Stiff Person Syndrome at MS Toronto
From Kyverna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Kyverna Therapeutics to Present Positive Data in Stiff Person Syndrome and Progressive Multiple Sclerosis at MSToronto2026
From Kyverna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Kyverna Therapeutics Reports Positive One-Year Data Demonstrating Durable Clinical Responses and Favorable Safety Profile for Miv-cel in Stiff Person Syndrome and Generalized Myasthenia Gravis
From Kyverna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Kyverna Therapeutics to Present at Upcoming Investor Conferences
From Kyverna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Kyverna Therapeutics Reports Pipeline Progress and Second Quarter 2026 Financial Results
From Kyverna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Kyverna Therapeutics and ElevateBio Enter into Commercial Manufacturing and Supply Agreement for Miv-cel
New agreement secures flexible and scalable manufacturing to support the U.S. commercial and global clinical supply of miv-cel 
From Kyverna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Kyverna Therapeutics Appoints Ritesh Srivastava as Chief Legal and Compliance Officer, Adding Leadership Strength to Support Commercial-Stage Transition
From Kyverna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Kyverna Therapeutics Highlights Updated Miv-cel Data at EULAR Demonstrating Substantial Reduction in Disease Activity in ACPA-Positive, Treatment Refractory Rheumatoid Arthritis
From Kyverna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Kyverna Therapeutics Names Greg Martini as Chief Financial Officer
Veteran biopharma leader joins to help lead Kyverna’s next phase of commercial growth 
From Kyverna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Kyverna Therapeutics to Present at Upcoming Investor Conferences
From Kyverna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Kyverna Therapeutics Announces Initiation of Rolling SPS BLA Submission and Reports First Quarter 2026 Financial Results
From Kyverna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Kyverna Therapeutics Appoints Nadia Dac, Seasoned Commercial Leader in Neurology and Rare Disease, as Chief Commercial Officer
Ms. Dac brings more than 30 years of experience successfully executing product launches and scaling commercial organizations for a range of therapeutic areas 
From Kyverna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Kyverna Presents Registrational Trial Primary Analysis for Miv-cel in Stiff Person Syndrome Demonstrating Statistically Significant, Durable Clinical Benefit Across All Endpoints in an Oral, Late-Breaker Session at AAN Annual Meeting
From Kyverna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Kyverna Presents Longer-Term Phase 2 Data for Miv-cel in Generalized Myasthenia Gravis at AAN, Demonstrating Deep, Durable Responses through 52 Weeks
From Kyverna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Kyverna Therapeutics to Host Conference Call on New Data Across Neuroimmunology Franchise at AAN 2026
From Kyverna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
From Kyverna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Kyverna Therapeutics to Present New Data from Neuroimmunology Franchise at AAN 2026
From Kyverna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Kyverna Therapeutics to Participate in Upcoming March Investor Conferences
From Kyverna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Kyverna Therapeutics Appoints Biotech Leaders Sravan Emany and Andrew Miller to Board of Directors
From Kyverna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Kyverna Therapeutics Appoints Mayo Pujols as Chief Technology Officer
Mr. Pujols brings more than 30 years of technical operations expertise to role, scaling commercial manufacturing for CAR T-cell therapies and complex biologics, as Kyverna advances towards launch of... 
From Kyverna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Kyverna Therapeutics Provides Corporate Update and Outlines 2026 Strategic Priorities at the J.P. Morgan Healthcare Conference
From Kyverna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Kyverna Therapeutics to Present at the J.P. Morgan 2026 Healthcare Conference
From Kyverna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Kyverna Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock
From Kyverna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Kyverna Therapeutics Announces Proposed Public Offering of Common Stock
From Kyverna Therapeutics, Inc.
Via GlobeNewswire
News headline image
ENDRA Life Sciences (NASDAQ: NDRA) Advances Health Tech (Alongside KYTX, RADX, GLSI IMNM) With a Next-Generation Treasury Strategy
Via AB Newswire
News headline image
Kyverna Therapeutics Announces Positive Topline Data from Registrational KYSA-8 Trial of Miv-cel (KYV-101) in Stiff Person Syndrome
From Kyverna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Kyverna Therapeutics to Report Topline Results from Registrational Phase 2 KYSA-8 Trial of KYV-101 in Stiff Person Syndrome
– Company to host live webcast and conference call Monday, December 15, 2025 at 8:00 am ET – 
From Kyverna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results
From Kyverna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Kyverna Therapeutics to Present at the Jefferies London Healthcare Conference
From Kyverna Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.